多发性骨髓瘤中多种Cereblon基因改变与来那度胺或泊马度胺获得性耐药相关
该研究利用455例患者全基因组测序和655例患者RNA测序数据,分析新诊断、来那度胺难治和泊马度胺难治队列中CRBN基因改变频率。发现点突变、拷贝丢失/结构变异和特定转录本随IMiD暴露逐步增加,泊马度胺难治时近三分之一患者有CRBN改变,且三种改变均与泊马度胺疗效不佳相关。
要点
- CRBN点突变、拷贝丢失/结构变异和exon 10剪接转录本随IMiD暴露递增。
- 泊马度胺难治患者中近三分之一存在CRBN改变。
- 来那度胺难治者中CRBN拷贝丢失/结构变异与泊马度胺疗效差相关。
核心结论
- CRBN点突变、拷贝丢失/结构变异和exon 10剪接转录本随IMiD暴露递增,并与泊马度胺疗效不佳相关。
研究设计与样本
- 回顾性分析455例患者全基因组测序数据,包括新诊断198例、来那度胺难治203例、泊马度胺难治54例。
- 回顾性分析655例患者RNA测序数据,包括新诊断437例、来那度胺难治176例、泊马度胺难治42例。
主要发现
- 随IMiD暴露进展,CRBN点突变、拷贝丢失/结构变异和exon 10剪接转录本频率逐步增加。
- 泊马度胺难治时近三分之一患者存在CRBN改变。
- 来那度胺难治患者中,三种CRBN改变均与泊马度胺疗效不佳相关,包括拷贝丢失和结构变异。
临床怎么用
- CRBN改变状态可能有助于选择序贯使用CRBN靶向药物的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emergence of drug resistance to all available therapies is the major challenge to improving survival in myeloma. Cereblon (CRBN) is the essential binding protein of the widely used immunomodulatory drugs (IMiDs) and novel CRBN E3 ligase modulator drugs (CELMoDs) in myeloma, as well as certain proteolysis targeting chimeras (PROTACs), in development for a range of diseases. Using whole-genome sequencing (WGS) data from 455 patients and RNA sequencing (RNASeq) data from 655 patients, including newly diagnosed (WGS, n = 198; RNASeq, n = 437), lenalidomide (LEN)-refractory (WGS, n = 203; RNASeq, n = 176), and pomalidomide (POM)-refractory cohorts (WGS, n = 54; RNASeq, n = 42), we found incremental increases in the frequency of 3 CRBN aberrations, namely point mutations, copy losses/structural variations, and a specific variant transcript (exon 10 spliced), with progressive IMiD exposure, until almost one-third of patients had CBRN alterations by the time they were POM refractory. We found all 3 CRBN aberrations were associated with inferior outcomes to POM in those already refractory to LEN, including those with gene copy losses and structural variations, a finding not previously described. This represents the first comprehensive analysis and largest data set of CBRN alterations in myeloma patients as they progress through therapy. It will help inform patient selection for sequential therapies with CRBN-targeting drugs.
引用
- Gooding S, Ansari-Pour N, Towfic F, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021. PMID: 33443552. doi:10.1182/blood.2020007081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。